Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates

@inproceedings{Lu2014PopulationPO,
  title={Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates},
  author={Dan Z Lu and Sandhya R Girish and Yuying Gao and Bei Wang and J Yi and Ellie Guardino and Meghna K Samant and Melody A. Cobleigh and Mothaffar F Rimawi and Pier Franco Conte and Jin Yan Jin},
  booktitle={Cancer Chemotherapy and Pharmacology},
  year={2014}
}
Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising the humanized monoclonal antibody trastuzumab linked to DM1, a highly potent cytotoxic agent. A population pharmacokinetic (PK) analysis was performed to estimate typical values and interindividual variability of T-DM1 PK parameters and the effects of clinically relevant covariates. Serum samples were collected from 671 patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic breast… CONTINUE READING
Highly Cited
This paper has 18 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-9 of 9 citations